JP2023553563A - Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 - Google Patents

Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 Download PDF

Info

Publication number
JP2023553563A
JP2023553563A JP2023536097A JP2023536097A JP2023553563A JP 2023553563 A JP2023553563 A JP 2023553563A JP 2023536097 A JP2023536097 A JP 2023536097A JP 2023536097 A JP2023536097 A JP 2023536097A JP 2023553563 A JP2023553563 A JP 2023553563A
Authority
JP
Japan
Prior art keywords
glp
composition
concentration
present
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553563A5 (https=
Inventor
ジェスパー スコドボーグ ビラジェン
リス ジエム
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2023553563A publication Critical patent/JP2023553563A/ja
Publication of JP2023553563A5 publication Critical patent/JP2023553563A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2023536097A 2020-12-16 2021-12-16 Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 Pending JP2023553563A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20214558.7 2020-12-16
EP20214558 2020-12-16
PCT/EP2021/086148 WO2022129312A1 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Publications (2)

Publication Number Publication Date
JP2023553563A true JP2023553563A (ja) 2023-12-22
JP2023553563A5 JP2023553563A5 (https=) 2024-12-23

Family

ID=74141273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536097A Pending JP2023553563A (ja) 2020-12-16 2021-12-16 Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物

Country Status (13)

Country Link
US (1) US20230405088A1 (https=)
EP (1) EP4262746A1 (https=)
JP (1) JP2023553563A (https=)
KR (1) KR20230121824A (https=)
CN (1) CN116723850A (https=)
AU (1) AU2021401137B2 (https=)
CA (1) CA3196989A1 (https=)
CL (1) CL2023001745A1 (https=)
IL (1) IL301891A (https=)
MX (1) MX2023006280A (https=)
TW (1) TW202241491A (https=)
WO (1) WO2022129312A1 (https=)
ZA (1) ZA202304233B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
IL301892A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
JP2024533153A (ja) * 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539713A (ja) * 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
JP2015524419A (ja) * 2012-07-23 2015-08-24 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2016531156A (ja) * 2013-09-13 2016-10-06 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、及びその組成物
JP2019214583A (ja) * 2016-12-09 2019-12-19 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
KR20200080331A (ko) * 2012-07-23 2020-07-06 질랜드 파마 에이/에스 글루카곤 유사체
KR102455171B1 (ko) * 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539713A (ja) * 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
JP2015524419A (ja) * 2012-07-23 2015-08-24 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2016531156A (ja) * 2013-09-13 2016-10-06 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、及びその組成物
JP2019214583A (ja) * 2016-12-09 2019-12-19 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Also Published As

Publication number Publication date
WO2022129312A1 (en) 2022-06-23
US20230405088A1 (en) 2023-12-21
KR20230121824A (ko) 2023-08-21
CN116723850A (zh) 2023-09-08
AU2021401137B2 (en) 2024-09-05
CL2023001745A1 (es) 2024-01-19
TW202241491A (zh) 2022-11-01
ZA202304233B (en) 2025-08-27
IL301891A (en) 2023-06-01
AU2021401137A1 (en) 2023-06-08
MX2023006280A (es) 2023-06-13
EP4262746A1 (en) 2023-10-25
CA3196989A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
CN113966226B (zh) 双重glp1/2激动剂的药物肠胃外组合物
JP2025121987A (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
JP2023553563A (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
JP7809117B2 (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260303